205 related articles for article (PubMed ID: 28363186)
1. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of different cervical cancer screening strategies in Mexico.
Beal CM; Salmerón J; Flores YN; Torres L; Granados-García V; Dugan E; Lazcano-Ponce E
Salud Publica Mex; 2014; 56(5):429-501. PubMed ID: 25604287
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
4. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
5. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
[TBL] [Abstract][Full Text] [Related]
6. Management of high-risk HPV-positive women for detection of cervical (pre)cancer.
Luttmer R; De Strooper LM; Steenbergen RD; Berkhof J; Snijders PJ; Heideman DA; Meijer CJ
Expert Rev Mol Diagn; 2016 Sep; 16(9):961-74. PubMed ID: 27459506
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
8. The budget impact of cervical cancer screening using HPV primary screening.
Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
[TBL] [Abstract][Full Text] [Related]
9. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
[TBL] [Abstract][Full Text] [Related]
12. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cervical cancer in women with ASCUS in the Brazilian Unified National Health System: cost-effectiveness of the molecular biology method for HPV detection.
Nomelini RS; Guimarães PD; Candido PA; Campos AC; Michelin MA; Murta EF
Cad Saude Publica; 2012 Nov; 28(11):2043-52. PubMed ID: 23147946
[TBL] [Abstract][Full Text] [Related]
14. The impact on women's health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium.
Tjalma WAA; Kim E; Vandeweyer K
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():171-181. PubMed ID: 28081908
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of strategies for cervical cancer prevention in India.
Chauhan AS; Prinja S; Srinivasan R; Rai B; Malliga JS; Jyani G; Gupta N; Ghoshal S
PLoS One; 2020; 15(9):e0238291. PubMed ID: 32870941
[TBL] [Abstract][Full Text] [Related]
16. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
[TBL] [Abstract][Full Text] [Related]
17. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
18. Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Primary HPV Screening Strategies and Triage With Cytology or Dual Stain for Cervical Cancer.
Tantitamit T; Khemapech N; Havanond P; Termrungruanglert W
Cancer Control; 2020; 27(1):1073274820922540. PubMed ID: 32372659
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.
Harper DM; Anderson RJ; Baker E; Yu TM
Cancer Prev Res (Phila); 2023 Jul; 16(7):393-404. PubMed ID: 37210751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
